Sucher Joseph F, Jones Stephen L, Montoya Isaac D
Assistant Professor of Surgery Weill Cornell Medical College, Division of Surgical Critical Care and Acute Care Surgery, Department of Surgery, 6550 Fannin Street Smith Tower 1661 Houston, TX 77030, USA.
Expert Opin Med Diagn. 2009 Jan;3(1):5-11. doi: 10.1517/17530050802644673.
US national healthcare expenditure reached over 2 trillion dollars in 2007. medical device expenditure has remained nearly a constant 6% of the total healthcare expenditure. medical technology may be one of the driving factors increasing healthcare costs. the number of medical device (which includes diagnostic tests) and laboratory equipment manufacturers, and investment in research for medical devices continue to rise. medical device manufacturers can receive a higher than average return on investment if they successfully navigate the food and drug administration (FDA) approval process.
this paper focuses on the series of steps a manufacturer can pursue to facilitate the introduction of a new device to the us market.
a review of the FDA regulations and current literature was conducted.
RESULTS/CONCLUSION: exemption from a full review by the FDA owing to substantial equivalence is one of the pathways a manufacturer can pursue for quicker and easier approval of the new device. three classes of devices are reviewed, as are some of the key regulations governing them. the regulations for advertising and promotion are still unclear because of the gray area that exists between the federal trade commission and the FDA. this paper concludes by summarizing the advertising and promotion regulations set forth by the FDA during the post-approval phase.
2007年美国全国医疗保健支出超过2万亿美元。医疗器械支出一直占医疗保健总支出的近6%。医疗技术可能是推动医疗成本上升的因素之一。医疗器械(包括诊断测试)和实验室设备制造商的数量以及对医疗器械研究的投资持续增长。如果医疗器械制造商能够成功通过食品药品监督管理局(FDA)的审批程序,他们可以获得高于平均水平的投资回报。
本文重点关注制造商为促进新设备进入美国市场可采取的一系列步骤。
对FDA法规和当前文献进行了综述。
结果/结论:由于实质等同性而免于FDA的全面审查是制造商可以寻求的使新设备更快、更容易获得批准的途径之一。对三类设备进行了审查,并介绍了一些管理它们的关键法规。由于联邦贸易委员会和FDA之间存在灰色地带,广告和促销法规仍不明确。本文通过总结FDA在批准后阶段制定的广告和促销法规得出结论。